Evidence map›Paper›PMID 37819454›Full record

ArticleArchives of toxicology2024

Evaluation of new alternative methods for the identification of estrogenic, androgenic and steroidogenic effects: a comparative in vitro/in silico study.

A Najjar, A Wilm, J Meinhardt, N Mueller, M Boettcher, J Ebmeyer, A Schepky, D Lange

Open access · hybridAbstract read
In one paragraph

Article in Archives of toxicology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.9field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

A NajjarBeiersdorf AG, Beiersdorfstr. 1-9, 20245, Hamburg, Germany. abdulkarim.najjar@beiersdorf.com.ORCID 0000-0003-4620-9830
A WilmBeiersdorf AG, Beiersdorfstr. 1-9, 20245, Hamburg, Germany.
J MeinhardtBeiersdorf AG, Beiersdorfstr. 1-9, 20245, Hamburg, Germany.
N MuellerBeiersdorf AG, Beiersdorfstr. 1-9, 20245, Hamburg, Germany.
M BoettcherBeiersdorf AG, Beiersdorfstr. 1-9, 20245, Hamburg, Germany.
J EbmeyerBeiersdorf AG, Beiersdorfstr. 1-9, 20245, Hamburg, Germany.
A SchepkyBeiersdorf AG, Beiersdorfstr. 1-9, 20245, Hamburg, Germany.
D LangeBeiersdorf AG, Beiersdorfstr. 1-9, 20245, Hamburg, Germany.
Beiersdorf (Germany) · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A suite of in vitro assays and in silico models were evaluated to identify which best detected the endocrine-disrupting (ED) potential of 10 test chemicals according to their estrogenic, androgenic and steroidogenic (EAS) potential compared to the outcomes from ToxCast. In vitro methods included receptor-binding, CALUX transactivation, H295R steroidogenesis, aromatase activity inhibition and the Yeast oestrogen (YES) and Yeast androgen screen (YAS) assays. The impact of metabolism was also evaluated. The YES/YAS assays exhibited a high sensitivity for ER effects and, despite some challenges in predicting AR effects, is a good initial screening assay. Results from receptor-binding and CALUX assays generally correlated and were in accordance with classifications based on ToxCast assays. ER agonism and AR antagonism of benzyl butyl phthalate were abolished when CALUX assays included liver S9. In silico final calls were mostly in agreement with the in vitro assays, and predicted ER and AR effects well. The efficiency of the in silico models (reflecting applicability domains or inconclusive results) was 43-100%. The percentage of correct calls for ER (50-100%), AR (57-100%) and aromatase (33-100%) effects when compared to the final ToxCast call covered a wide range from highly reliable to less reliable models. In conclusion, Danish (Q)SAR, Opera, ADMET Lab LBD and ProToxII models demonstrated the best overall performance for ER and AR effects. These can be combined with the YES/YAS assays in an initial screen of chemicals in the early tiers of an NGRA to inform on the MoA and the design of mechanistic in vitro assays used later in the assessment. Inhibition of aromatase was best predicted by the Vega, AdmetLab and ProToxII models. Other mechanisms and exposure should be considered when making a conclusion with respect to ED effects.

Indexed as

AndrogensEndocrine DisruptorsAromataseEstrogensEstroneReceptors, AndrogenSaccharomyces cerevisiaeAndrogensAromataseEndocrine DisruptorsEstrogensEstroneReceptors, AndrogenAndrogenEATSEndocrine-disrupting potentialIn vitro/In silicoNAMsNGRAOestrogenSteroidogenesisToxCast

Identifiers

PMID37819454
PMCPMC10761396
OpenAlexW4387530837

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.